SynthesisESMO open2023

Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis.

A Rizzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.